Effectiveness and safety of montelukast, a leukotriene receptor antagonist, compared to inhaled cromolyn in moderate asthmatic children ages 6 to 11.

被引：0
|
作者：
Edelman, JM [1 ]
Milewski, KA [1 ]
Turpin, JA [1 ]
Santanello, NC [1 ]
Bird, SR [1 ]
Rader, CA [1 ]
机构：
[1] Merck & Co Inc, Horsham, PA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 1999年 / 103卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
510
引用
收藏
页码：S134 / S134
页数：1
相关论文
共 17 条
  • [1] The safety of oral montelukast compared to inhaled cromolyn in asthmatic children
    Edelman, JM
    Firriolo, KM
    Bird, SR
    Dellea, PS
    Menten, J
    Leff, JA
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (02) : S111 - S111
  • [2] Parent and child satisfaction for montelukast, a leukotriene receptor antagonist, compared with inhaled beclomethasone in asthmatic children aged 6 to 11
    Firriolo, KM
    Edelman, JM
    Bratton, D
    Santanello, N
    Bird, SR
    Rader, CA
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 105 (01) : S25 - S25
  • [3] NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast
    Bisgaard, H
    Loland, L
    Anhoj, J
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (04) : 1227 - 1231
  • [4] Patient and parent preference and satisfaction for Montelukast, a leukotriene receptor antagonist, versus inhaled cromolyn in children with asthma: Comparison between racial groups
    Macintyre, PK
    Firriolo, KM
    Santanello, NC
    Bird, SR
    Edelman, JM
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (02) : S250 - S250
  • [5] Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
    Löfdahl, CG
    Reiss, TF
    Leff, JA
    Israel, E
    Noonan, MJ
    Finn, AF
    Seidenberg, BC
    Capizzi, T
    Kundu, S
    Godard, P
    BMJ-BRITISH MEDICAL JOURNAL, 1999, 319 (7202): : 87 - 90
  • [6] Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients
    Tohda, Y
    Fujimura, M
    Taniguchi, H
    Takagi, K
    Igarashi, T
    Yasuhara, H
    Takahashi, K
    Nakajima, S
    CLINICAL AND EXPERIMENTAL ALLERGY, 2002, 32 (08): : 1180 - 1186
  • [7] RELATIVE EFFECTIVENESS OF INHALED CORTICOSTEROIDS AND LEUKOTRIENE-RECEPTOR ANTAGONISTS TO PREVENT MODERATE-TO-SEVERE EXACERBATIONS AMONG ASTHMATIC CHILDREN
    Blais, L.
    Kettani, F. Z.
    Lemiere, C.
    Beauchesne, M. F.
    Perreault, S.
    Elftouh, N.
    VALUE IN HEALTH, 2008, 11 (06) : A446 - A446
  • [8] Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: A randomized, open-label, crossover study
    Bukstein, DA
    Bratton, DL
    Firriolo, KM
    Estojak, J
    Bird, SR
    Hustad, CM
    Edelman, JM
    JOURNAL OF ASTHMA, 2003, 40 (05) : 475 - 485
  • [9] Step-Down Therapy in Asthmatic Children Receiving both Inhaled Corticasteroids and Leukotriene Receptor Antagonist
    Huynh, P.
    Morphew, T.
    Ratnayake, A.
    Luu, C.
    Scott, L.
    Nichols, B.
    Kwong, K.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S156 - S156
  • [10] Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids
    Reiss, TF
    Sorkness, CA
    Stricker, W
    Botto, A
    Busse, WW
    Kundu, S
    Zhang, J
    THORAX, 1997, 52 (01) : 45 - 48
12